ITV GMB’s Dr Hilary Jones explains UK doctors’ U-Turn on ibuprofen to cure COVID-19

ITV GMB’s Dr Hilary Jones explains UK doctors’ U-Turn on ibuprofen to cure COVID-19

Speaking on ITV on Thursday, Dr Hilary Jones claimed it was “ironic” that some doctors now were testing the use of ibuprofen to cure . Asked by Piers Morgan to address the news British doctors are trialling the anti-inflammatory drug on COVID-19 patients, Dr Jones said: “Anti-Inflammatories as such as ibuprofen, could have an effect on suppressing the inflammation in blood vessels.


“What we know about COVID-19 is that it’s not just a respiratory illness at all, it affects many organs in the body, largely because the lining of blood vessels becomes inflamed.

“When the linings of blood vessels become inflamed it helps the blood to clot and any plaque, any deposit that are already in the arteries, those blood clots can form and they do form in many patients with COVID-19 who have very severe consequences.

“So an anti-inflammatory like ibuprofen, potentially, could help with that inflammation and suppress some of the consequences of COVID-19.

“Preventing people to go onto ventilators and going into ICU.

“So it’s interesting and it’s ironic because initially in the outbreak many people thought it could actually make the situation worse.”

READ MORE: Coronavirus lockdown is affecting sleeping patterns, shock study

British doctors are trialling a formulation of anti-inflammatory ibuprofen to see if it reduces respiratory failure in patients with severe symptoms of COVID-19.

The trial involves a particular formulation of ibuprofen, which researchers said had been shown to be more effective than standard ibuprofen for treating severe acute respiratory distress syndrome (ARDS), a complication of COVID-19.

The formulation is already licensed for use in Britain for other conditions.

“If successful, the global public health value of this trial result would be immense given the low cost and availability of this medicine,” said Matthew Hotopf, director of NIHR Maudsley Biomedical Research Centre.

The trial, known as “LIBERATE”, will be a randomised study, with the recruitment of up to 230 patients expected over the coming months.

It is being run by Guy’s & St Thomas’ NHS Foundation Trust in London, King’s College London (KCL) and pharmaceutical organisation the SEEK Group.

In March, France’s health minister said people should not use anti-inflammatory drugs such as ibuprofen if they have symptoms of COVID-19, the disease caused by the new coronavirus.

However, US, British and European Union drug regulators as well as Reckitt Benckiser, which makes Nurofen, have all said there is no evidence that ibuprofen makes COVID-19 worse.

Coronavirus map LIVE: Terrifying stats spark panic in Berlin and Spain [LIVE BLOG]
Thousands of COVID tests voided after decision to send to US backfires [REACTION]
UK’s coronavirus death toll is officially higher than the Blitz [DATA]

Mitul Mehta, director of KCL’s Centre for Innovative Therapeutics, said that possible well-known gastric side effects from ibuprofen meant that paracetamol was better to relieve COVID-19 symptoms in its early stages.

But he added there was no evidence to back up the French claims that ibuprofen worsens COVID-19 symptoms, saying the formulation being used in the trial should lessen the possible side effects.

“There’s no way these early reports would’ve been talking about this different formulation,” Mehta told Reuters.

“The trial is the right forum in which to test the side effects and to test the efficacy.”

Published at Thu, 04 Jun 2020 07:58:00 +0000